Search Results 2921-2930 of 17945 for rheumatoid arthritis

1. Robotic surgery - Doctors & Departments - Mayo Clinic

   ... arthritis, Thrower's shoulder, SLAP tear, Biceps tendinitis, Rotator cuff tear, Shoulder instability, Patellofemoral instability, Pectoralis tear, Shoulder ...

2. My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors - Mayo Clinic

   ... factor for neurosensory retinal detachment, retinal vein occlusion (RVO), or neovascular macular degeneration; Presence of any of the following conditions ...

3. Summit Healthcare Regional Medical Center in Arizona joins Mayo Clinic Care Network

   For more information, visit mayoclinic.org/about-mayo-clinic or newsnetwork.mayoclinic.org/. Mayo Clinic Minute: Stem cells reduce pain of knee arthritis · 7 ...

4. Health Topics - Mayo Clinic News Network

   Mayo Clinic experts say time is most critical factor for better stroke outcomes. Kevin Punsky. October 20, 2022. First · Previous ... 137 · 138 · 139 · 140 ...

5. Antiphospholipid syndrome - Doctors and departments - Mayo Clinic

   Rheumatology · Vascular centers. Areas that research this condition. Neurology Research · By Mayo Clinic Staff · Request an appointment · Diagnosis & treatment.

6. Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) - Mayo Clinic

   Participants therapeutically anticoagulated with warfarin, direct thrombin inhibitors, direct factor Xa inhibitors, or heparin are excluded from enrollment.

7. Virotherapy Clinical Trials - Mayo Clinic Research

   The purpose of this study is to look at the safety and immune response to a vaccine used in patients previously treated for HER2 (human epidermal growth factor ...

8. A Study to Compare the Effectiveness and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas - Mayo Clinic

   ... factor [TNF], anti-IL-6, or anti-IL-6R). Radiation within 4 weeks prior to signing the ICF. Subjects must have progressive disease in irradiated lesions or ...

9. VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer - Mayo Clinic

   Tumors lack activating epidermal growth factor receptor (EGFR) mutations or ALK rearrangement (no EGFR or ALK testing is required if a subject has a KRAS ...

10. In the Loop: Brittle bone disease can't dim this little girl's unbreakable spirit

    Mayo Clinic Minute: How genetics factor into treating alcohol use disorder. Related Articles. Mayo Clinic Q&A: Strategies for calming back-to-school anxiety ...